High frequency of MAGE‐A4 and MAGE‐A9 expression in high‐risk bladder cancer
Authors:
Open Access
- 14 July 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 125 (6) , 1365-1371
Abstract
Cancer‐testis (CT) genes encode proteins that are ideal targets for cancer immunotherapy because of their restricted expression in normal tissues and frequent expression in cancers. We previously observed that MAGE‐A9 was one of the CT genes most frequently expressed in bladder tumors. To confirm that observation and evaluate the potential prognostic value of MAGE‐A9 protein, we analyzed its expression by immunohistochemistry in 493 primary bladder tumors and 33 lymph node metastases, in comparison with MAGE‐A4 protein, also frequently expressed in bladder tumors. Overall, MAGE‐A4 and MAGE‐A9 were observed, respectively, in 38% and 63% of nonmuscle‐invasive tumors, 48% and 57% of muscle‐invasive tumors, 65% and 84% of carcinomas in situ and in 73% and 85% of lymph node metastases. Expression was associated with higher grade (MAGE‐A4, p = 0.007; MAGE‐A9, p = 0.012). In multivariate Cox regression analyses, expression of MAGE‐A9 in pTa tumors was associated with recurrence (HR = 1.829; p = 0.010). In univariate analyses, MAGE‐A4 expression in these same tumors was associated with progression to muscle‐invasive cancer (HR = 7.417, p = 0.013). MAGE‐A9 expression was even more predictive of progression as all tumors that progressed expressed this antigen. In muscle‐invasive bladder tumors, no association was found between expression of either MAGE and bladder cancer‐specific death. In conclusion, MAGE‐A9 is a target of choice for bladder cancer immunotherapy as it is expressed in 60% of bladder tumors, predominantly high‐grade tumors, and at higher frequency in pTis and metastatic tumors. Moreover, in pTa tumors, an immunotherapy targeting MAGE‐A9 could be protective against recurrence and progression to more advanced cancer. © 2009 UICCKeywords
This publication has 17 references indexed in Scilit:
- Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancerCancer, 2008
- Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvementBiomedicine & Pharmacotherapy, 2007
- MAGE‐A9 mRNA and protein expression in bladder cancerInternational Journal of Cancer, 2007
- Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial CarcinomaClinical Cancer Research, 2006
- Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1Immunology & Cell Biology, 2006
- Cancer/testis antigens, gametogenesis and cancerNature Reviews Cancer, 2005
- Prognostic relevance of MAGE‐A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray studyInternational Journal of Cancer, 2002
- Monoclonal antibody 57B stains tumor tissues that express geneMAGE-A4International Journal of Cancer, 2000
- The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic indexBritish Journal of Urology, 1998
- Expression of mage genes in transitional‐cell carcinomas of the urinary bladderInternational Journal of Cancer, 1995